Bradley Duffy

Array ( [id] => 10784203 [patent_doc_number] => 20160130358 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-12 [patent_title] => 'CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES' [patent_app_type] => utility [patent_app_number] => 14/851348 [patent_app_country] => US [patent_app_date] => 2015-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 69178 [patent_no_of_claims] => 54 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14851348 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12724255 [patent_doc_number] => 20180133252 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2018-05-17 [patent_title] => CHIMERIC RECEPTORS AND USES THEREOF IN IMMUNE THERAPY [patent_app_type] => utility [patent_app_number] => 15/509133 [patent_app_country] => US [patent_app_date] => 2015-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26525 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -71 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15509133 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12724255 [patent_doc_number] => 20180133252 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2018-05-17 [patent_title] => CHIMERIC RECEPTORS AND USES THEREOF IN IMMUNE THERAPY [patent_app_type] => utility [patent_app_number] => 15/509133 [patent_app_country] => US [patent_app_date] => 2015-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26525 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -71 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15509133 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11971219 [patent_doc_number] => 20170275374 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-28 [patent_title] => 'TROPHOBLAST GLYCOPROTEIN (5T4, TPBG) SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY' [patent_app_type] => utility [patent_app_number] => 15/506643 [patent_app_country] => US [patent_app_date] => 2015-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 16017 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15506643 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10712738 [patent_doc_number] => 20160058884 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-03 [patent_title] => 'METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS' [patent_app_type] => utility [patent_app_number] => 14/843769 [patent_app_country] => US [patent_app_date] => 2015-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 19137 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14843769 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11949506 [patent_doc_number] => 20170253658 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-07 [patent_title] => 'CD94/NKG2A AND/OR CD94/NKG2B ANTIBODY, VACCINE COMBINATIONS' [patent_app_type] => utility [patent_app_number] => 15/506263 [patent_app_country] => US [patent_app_date] => 2015-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 16074 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15506263 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10693750 [patent_doc_number] => 20160039896 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-11 [patent_title] => 'POLYPEPTIDES TARGETING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 AND ALPHA V BETA 3 INTEGRIN' [patent_app_type] => utility [patent_app_number] => 14/828330 [patent_app_country] => US [patent_app_date] => 2015-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 18711 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14828330 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10693749 [patent_doc_number] => 20160039895 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-11 [patent_title] => 'POLYPEPTIDES TARGETING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 AND ALPHA V BETA 3 INTEGRIN' [patent_app_type] => utility [patent_app_number] => 14/828319 [patent_app_country] => US [patent_app_date] => 2015-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 18715 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14828319 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12058625 [patent_doc_number] => 20170334967 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-23 [patent_title] => 'TREATMENT OF CANCER USING GFR ALPHA-4 CHIMERIC ANTIGEN RECEPTOR' [patent_app_type] => utility [patent_app_number] => 15/503971 [patent_app_country] => US [patent_app_date] => 2015-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 96478 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15503971 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11850326 [patent_doc_number] => 20170224818 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-10 [patent_title] => 'SUBCUTANEOUSLY ADMINISTERED BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF CANCER' [patent_app_type] => utility [patent_app_number] => 15/502782 [patent_app_country] => US [patent_app_date] => 2015-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 24557 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 16 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15502782 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12092574 [patent_doc_number] => 20170349668 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-07 [patent_title] => 'OPTIMIZED CROSS-SPECIES SPECIFIC BISPECIFIC SINGLE CHAIN ANTIBODY CONTRUCTS' [patent_app_type] => utility [patent_app_number] => 15/329672 [patent_app_country] => US [patent_app_date] => 2015-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 28651 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15329672 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15576491 [patent_doc_number] => 10578621 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-03 [patent_title] => Biomarker PNCK for predicting effect of a dual-targeting agent [patent_app_type] => utility [patent_app_number] => 14/814165 [patent_app_country] => US [patent_app_date] => 2015-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 22678 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14814165 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10437124 [patent_doc_number] => 20150322136 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-12 [patent_title] => 'BINDING POLYPEPTIDES WITH OPTIMIZED SCAFFOLDS' [patent_app_type] => utility [patent_app_number] => 14/812695 [patent_app_country] => US [patent_app_date] => 2015-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 61 [patent_no_of_words] => 45868 [patent_no_of_claims] => 73 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14812695 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11979342 [patent_doc_number] => 20170283497 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-05 [patent_title] => 'ROR1 (NTRKR1) SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY' [patent_app_type] => utility [patent_app_number] => 15/329932 [patent_app_country] => US [patent_app_date] => 2015-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 22238 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15329932 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10678070 [patent_doc_number] => 20160024214 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-28 [patent_title] => 'Antibodies Against Human NKG2D and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 14/809680 [patent_app_country] => US [patent_app_date] => 2015-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 60511 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14809680 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11400418 [patent_doc_number] => 20170020957 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-26 [patent_title] => 'METHODS OF REDUCING THE NEED FOR SURGERY IN PATIENTS SUFFERING FROM BENIGN PROSTATIC HYPERPLASIA' [patent_app_type] => utility [patent_app_number] => 14/808731 [patent_app_country] => US [patent_app_date] => 2015-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23080 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14808731 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11851724 [patent_doc_number] => 20170226216 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-10 [patent_title] => 'BCMA CHIMERIC ANTIGEN RECEPTORS' [patent_app_type] => utility [patent_app_number] => 15/328278 [patent_app_country] => US [patent_app_date] => 2015-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 36213 [patent_no_of_claims] => 86 [patent_no_of_ind_claims] => 47 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15328278 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11283759 [patent_doc_number] => 09499603 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-22 [patent_title] => 'PD-1 antibodies' [patent_app_type] => utility [patent_app_number] => 14/802076 [patent_app_country] => US [patent_app_date] => 2015-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 55 [patent_figures_cnt] => 46 [patent_no_of_words] => 20427 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 297 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14802076 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12166937 [patent_doc_number] => 09885704 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-02-06 [patent_title] => 'Reagents and methods for cancer treatment and prevention' [patent_app_type] => utility [patent_app_number] => 14/800412 [patent_app_country] => US [patent_app_date] => 2015-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 9600 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14800412 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17236694 [patent_doc_number] => 11180566 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-23 [patent_title] => Antibodies that bind human CD27 and uses thereof [patent_app_type] => utility [patent_app_number] => 14/790247 [patent_app_country] => US [patent_app_date] => 2015-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 49 [patent_no_of_words] => 34325 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14790247 [rel_patent_id] =>[rel_patent_doc_number] =>)